Nakagoe T, Hirota M, Hiratani K, Fukushima K, Shimoyama T, Miura T, Tomita M, Hara K, Ifuku M
1st Dept. of Surgery, Nagasaki Univ. School of Med.
Gan No Rinsho. 1989 Mar;35(4):455-61.
The clinical usefulness as a tumor-associated antigen of the new monoclonal antibody CSLEX1, which reacts with the sialylated LewisX antigen, has been evaluated serologically in 141 patients with a gastric cancer. The serum sialylated LewisX was measured by fluorescent EIA. The percent positive figure of these gastric cancer patients was 17.0% (24/141), which indicates a significant increase when compared with that of the controls. The percent-positive values, according to the clinical stage, were 9.2%, 9.1%, 15.6%, and 36.4% for stages I, II, III, and IV, respectively. The degree of liver metastasis and peritoneal dissemination of the cancer correlated with the percent-positive values of the antigen. This suggests that sialylated LewisX is useful as a tumor-associated antigen.
新的单克隆抗体CSLEX1可与唾液酸化路易斯X抗原发生反应，作为一种肿瘤相关抗原，其临床应用价值已在141例胃癌患者中进行了血清学评估。通过荧光酶免疫测定法检测血清唾液酸化路易斯X。这些胃癌患者的阳性率为17.0%（24/141），与对照组相比有显著升高。根据临床分期，I、II、III和IV期的阳性率分别为9.2%、9.1%、15.6%和36.4%。癌症的肝转移程度和腹膜播散与该抗原的阳性率相关。这表明唾液酸化路易斯X可作为一种肿瘤相关抗原。
